Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 289

1.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

PMID:
23117885
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

PMID:
22710436
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

PMID:
24101480
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.

Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y.

Int J Cancer. 2013 Nov;133(9):2225-33. doi: 10.1002/ijc.28202. Epub 2013 May 9.

PMID:
23575870
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH.

Cancer Discov. 2013 Sep;3(9):1020-9. doi: 10.1158/2159-8290.CD-13-0226. Epub 2013 Jun 18.

PMID:
23779130
[PubMed - indexed for MEDLINE]
6.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
[PubMed - indexed for MEDLINE]
7.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

PMID:
20823238
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Peacock SO, Fahrenholtz CD, Burnstein KL.

Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.

PMID:
23023561
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22.

PMID:
23699654
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

PMID:
23493310
[PubMed - indexed for MEDLINE]
Free Article
11.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
[PubMed - indexed for MEDLINE]
12.

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y.

Cancer Res. 2009 Mar 15;69(6):2305-13. doi: 10.1158/0008-5472.CAN-08-3795. Epub 2009 Feb 24.

PMID:
19244107
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
[PubMed - indexed for MEDLINE]
14.

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

Shiota M, Yokomizo A, Takeuchi A, Itsumi M, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Prostate. 2014 Jun;74(9):959-69. doi: 10.1002/pros.22813. Epub 2014 Apr 17.

PMID:
24740858
[PubMed - indexed for MEDLINE]
15.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

PMID:
23842682
[PubMed - indexed for MEDLINE]
16.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
[PubMed - indexed for MEDLINE]
17.

Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.

Lim AC, Attard G.

Curr Drug Targets. 2013 Apr;14(4):408-19.

PMID:
23565754
[PubMed - indexed for MEDLINE]
18.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
[PubMed - indexed for MEDLINE]
19.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

PMID:
20644256
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Schrader AJ, Schrader MG, Cronauer MV.

Eur Urol. 2013 Jul;64(1):169-70. doi: 10.1016/j.eururo.2013.04.024. No abstract available.

PMID:
23746320
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk